PHARMACOLOGY

S.No	Торіс
	Experimental
1.	Impact of dapagliflozin therapy on glycaemic control and daily insulin
	requirement in subjects with Type 2 diabetes mellitus: A prospective study.
2.	Comparison of atorvastatin and pitavastatin regarding their impact on
	glycaemic parameters in newly diagnosed subjects with dyslipidaemia: An
	open label randomized controlled study.
3.	An open label randomized study to evaluate the efficacy and safety of
	alternate Versus daily teneligliptin therapy in Type 2 diabetic subjects who
	failed to achieve glycaemic control with metformin and sulfonylureas.
4.	Comparison of Ferrous sulphate (old drug) Versus Ferrous ascorbate
	(relatively new drug) in the treatment of iron-deficiency anaemia in
	pregnancy with regard to efficacy and tolerability.
5.	Comparison between S(-) Etodolac, Meloxicam and Diclofenac in knee
	osteoarthritis with regard to pain, functionality and adverse effects.
6.	Experimental study of effectiveness of anxiolytic effect of various drugs
	including gabapentinoids in animal models of anxiety.
7.	Oral melatonin Versus standard oral therapy for insomnia: A randomized
	trial.
8.	Efficacy of anti-hypertensive drug therapy when it is given in morning,
	evening or individed dose: A randomized trial.
9.	A prospective study of prescription pattern/drug utilization pattern of
	Cephalosporins in a tertiary care hospital.
10.	A prospective study of adverse reaction profile to commonly used anti-
	coagulants in stroke management.
11.	Single dose Versus divided dose of atorvastatin for dyslipidaemia: A
42	randomized trial.
12.	Efficacy and safety of prophylactic iron therapy in adolescent girls: A proof
42	of concept study.
13.	To study the impact of a metformin on inflammatory markers in patients of
	Type 2 diabetes mellitus: A before and after study.
14.	Effect of patient medication counselling on medication errors in
	administration, and the impact on medication adherence in patients having
	diabetes and hypertension.

15.	To study the impact of sertraline as an antidepressant in patients with renal
	dysfunction.
16.	To perform the pharmacovigilance study of a new anti-epileptic drugs in
ı	patients attending neurology clinics.
17.	An open label study of amilsupride in behavioural & psychological
	symptoms of vascular dementia.
18.	Role of mobile text reminders in improving medication adherence and
	quality of life, among the geriatric population treated with multiple drugs.
19.	Smart phone application-based intervention and improvement of
	medication adherence in psychiatric patients.
20.	Knowledge, attitude and practices of adverse drug monitoring among
	medical students.
21.	Reducing Drug Wastage by Dose Modification and Discontinuation of
	therapy for addressing polypharmacy in elderly.
22.	An interventional study of metformin for improving treatment compliance
	by Use of Artificial Intelligence (e.g. App) for lifestyle diseases e.g.
	hypertension, diabetes etc.
23.	Effectiveness and adverse effect profile of different drugs for neuropathic
25.	pain.
	pani.
24.	An open label trial for Alpha-2 Delta ligands for treatment of epilepsy in
	tertiary care institute.
25.	An open label Trial of baclofen vs tolperisone in cerebral palsy.
26.	Open label Trial of magnesium plus riboflavin plus lifestyle measures vs
	lifestyle measures in migraine.
27.	An open label trial of pulse steroids vs oral steroids in prevention of
	complications of meningitis.
28.	An open label trial of meropenem in uncomplicated pyelonephritis caused
	by ESCR Enterobacteriaceae.
	Observational (Descriptive)
29.	Comparison of treatment satisfaction, efficacy and safety of sodium-glucose
	co-transporter-2 (SGLT2) inhibitors among geriatric patients with Type 2
	diabetes mellitus: A cross-sectional observational study.
30.	diabetes mellitus: A cross-sectional observational study. A real-world scenario and focused pharmacovigilance of genitourinary adverse effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors.

31.	Efficacy and safety of prophylactic iron therapy in adolescent girls: A proof
	of concept study.
32.	Comparative study of risperidone and quetiapine in reducing aggression in
	patients with behavioural & psychological symptoms of dementia.
33.	Comparative study of sertraline and ecitalopram in patients with Parkinson's
	disease with depression.
34.	Drug utilization study of combined herbal drugs-modern medicines used in
	treatment of Musculo-skeletal conditions
35.	Drug-herb interactions between metformin and the herbs identified as most
	commonly used in Type 2 diabetes.
36.	Monitoring of Adverse Drug Reactions among drug resistant TB patients.
37.	Drug Induced Liver Injury (DILI) in patients taking methotrexate therapy.
38.	Screening of phytochemicals/extract fractions using animal models (or
	simulations) e.g. screening of cardioprotective activity of using Langendorf
	apparatus.
39.	Pharmacogenetics of Oral Anticoagulants (e.g., warfarin) to Risk of Adverse
	Drug Reactions.
40.	Evaluation of antibacterial utilization using WHO indicators for
	strengthening 'Antibiotic Stewardship Programme'.
41.	Antibiotic stewardship-Pharmacovigilance of Antimicrobial resistance
	(AMR).
42.	Treatment outcomes of tuberculosis and with diabetes as comorbidity.
43.	Therapeutic drug monitoring (TDM) of Anticancer drugs.
44.	Drug utilisation review (DUR) and Adverse drug reactions (ADR).
45.	Pharmacoeconomics studies using standard study parameters such as
	economic evaluation of pharmaceuticals, cost-effectiveness analysis, cost-
	minimisation analysis, cost-benefit analysis, cost-utility analysis, Quality-
	adjusted life years (QALY) analysis of commonly used drugs in India.
46.	Survey of medication errors and their risk factors in tertiary care hospital
	setting.
47.	Medication non-adherence in organ (kidney) transplant recipients beyond
	the first year and associated risk factors.
48.	Focused pharmacovigilance study of Monoclonal antibodies used in
	rheumatological indications.
49.	Focused pharmacovigilance study of JAK-inhibitors (Janus-Kinase) used in
	rheumatological indications.

50.	Focused pharmacovigilance study of oral iron chelators used in
30.	transfusion-dependent thalassemia patients.
51.	Observational study of use of off- label use adult preparations for children,
J	including problems of crushing adult tablets.
52.	Evaluation of Medical Adherence in chronic diseases and factors affecting
<i>5</i> <u>_</u> ,	it.
53.	An open label study of lamotrigine on cognitive profile in children when
	used a monotherapy.
54.	Study of prescription pattern of antidiabetic drugs used in primary care
	compared to tertiary care.
55.	Predictors of compliance to antihypertensive drugs and Quality of Life of
Í	Patients with long standing hypertension.
56.	Medication adherence in patients of diabetes mellitus Type 1 and 2 and
	ways to improve it.
57.	Focused pharmacovigilance study of different parenteral iron preparations
	with special emphasis on incidence or prevalence of acute hypersensitivity
	reactions.
58.	Cost effectiveness analysis of metformin monotherapy Versus dual therapy
	with metformin and vildagliptin in initiation of treatment for patients of
	Type-2 Diabetes Miletus.
59.	Assessment of perceptions and evaluation of the quality of generics within
	the local health system: Implications for public health.
60.	To study the prevalence of antimicrobial drug resistance in patients with
	urinary tract infection attending the urology clinic in the district/tertiary care
	hospital.
61.	Role of periodic medication review (PMR) by a pharmacologist, in improving
	medication adherence in patients suffering from chronic orthopaedic
	conditions.
62.	Pharmacovigilance study drugs used in dyspepsia.
63.	Standardisation of tacrolimus therapeutic levels for prevention of graft
	rejection after renal transplant in the Indian population.
64.	Adverse reactions monitoring of drugs used in resistant malaria infection.
65.	Frequency and predictors of metronidazole induced neuropathy at a
	gastroenterology clinics of a tertiary care centre.
66.	Predictors of compliance to regular dose of inhalers in chronic childhood
	asthma.

67.	Drug utilization study and adverse drug reaction in neonatal care units in a
• • •	tertiary care hospital: a longitudinal observational study.
68.	Treatment outcome of Isoniazid mono-resistance tuberculosis patients.
69.	Evaluation of the prescription pattern of drugs in neurology outpatient
	department of a tertiary care hospital.
70.	Clinical correlation between subclinical hypothyroidism and plasma levels of
	commonly prescribed antiepileptic drugs.
71.	Predictors of sodium valproate induced weight gain and management by
• 	topiramate: an open label trial.
72.	Drug utilization study on inappropriate prescription of corticosteroids in
	chronic painful musculoskeletal conditions in tertiary centre.
73.	Drug utilization study on inappropriate prescription of benzodiazepines
	among elderly in tertiary care centre.
74.	Impact of a procalcitonin testing on antibiotic Use and Outcomes in the
	Paediatric/medical Intensive Care Unit.
75.	Deprescribing as a tool for improving safety of medications in geriatric
	populations.
76.	Deprescribing antibiotics as a potential tool for addressing antimicrobial
	resistance in tertiary care centre.
77.	Predictors and compliance to Augmentation Treatments for Improving
	Schizophrenia Treatment outcomes.
78.	Cost effectiveness and cost benefit analysis of anaemia treatment with oral
	or IV iron Supplementation in pregnant / non-pregnant women.
79.	A survey of off label medications (e.g., piracetam) for paediatric
	neurological patients in a tertiary care hospital.
80.	Treatment outcomes in complicated Urine Tract Infections treated with
	Faropenem – An observational study.
81.	Adverse drug reaction monitoring of TB patients taking anti retroviral
	drugs.
82.	A real-world scenario and focused pharmacovigilance of genitourinary
	adverse effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors.
	Implementation Research
83.	An implementation research study of assessment of medication adherence
	for anti-hypertensives therapy among patients at a tertiary care facility and
	identification of barriers and facilitators.